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Dilated cardiomyopathy (DCM) is defined by the presence of left 
ventricular systolic dysfunction and dilatation in the absence of 
abnormal loading conditions (e.g hypertension or valve disease) or 
coronary artery disease sufficient to cause global systolic impairment.1 
Right ventricular dilation and dysfunction may be present, but 
are not necessary for the diagnosis. DCM is an important cause of 
heart failure, and a common indication for heart transplantation.2 
The clinical and morphological diversity of DCM reflects the 
broad spectrum of distinct underlying molecular and environmental 
causes. The prevalence of DCM is estimated to be 36.5/100 000 
in a US population.3 There are no population-based studies of the 
epidemiology of DCM in sub-Saharan Africa.4 Most cases of DCM 
are thought to be sporadic or acquired.5 However, in many cases the 
disease is inherited and is termed familial DCM, which may account 
for up to 20 - 50% of DCM in Western populations.5-8 
Familial DCM is principally caused by genetic mutations in 
genes that encode cytoskeletal, nuclear and sarcomeric proteins in 
the cardiac myocyte.9 In addition, modifying genes, lifestyle and 
additional factors influence onset of disease, disease progression and 
prognosis.10 Pedigree analysis in familial DCM is most consistent with 
autosomal dominant (AD) inheritance with variable penetrance.11
We know of no information on the frequency and clinical genetics 
of familial DCM in Africa.12 Our aims were: (i) to describe the 
frequency of familial DCM in patients who were diagnosed with 
DCM and followed up in a cardiomyopathy clinic at the Cardiac 
Clinic, Groote Schuur Hospital (GSH), Cape Town, from 1 February 
1996 to 31 December 2009; (ii) to determine, through pedigree 
analysis, the likely modes of inheritance of familial DCM in this 
cohort; and (iii) to address the implications of the findings for the 
clinical evaluation of patients with unexplained DCM.
Methods
Study design
This was a retrospective hospital-based study of the frequency 
and clinical genetics of familial DCM in a cohort of DCM patients 
referred to the cardiomyopathy clinic in the GSH Cardiac Clinic. The 
frequency of familial DCM was based on a detailed family history 
in all individuals and family screening of first-degree relatives of 
probands with a positive history for confirmation of familial disease. 
Familial DCM was defined as the presence of DCM in at least one 
first-degree relative of the proband and/or sudden unexplained death 
under the age of 35 years in a first-degree relative.13 
Study population
We reviewed the medical records of all patients evaluated for a cause 
of cardiomyopathy from 1 February 1996 to 31 December 2009. 
These patients were seen in a dedicated cardiomyopathy clinic, 
where one of the authors (BMM) has a special interest in disorders 
of heart muscle, and do not reflect the total experience of the GSH 
Cardiac Clinic. Patients included were those with DCM, as evidenced 
by clinical signs and symptoms of heart failure associated with left 
ventricular dilatation and a left ventricular ejection fraction less than Corresponding author: B M Mayosi (bongani.mayosi@uct.ac.za)
Cardiac Clinic and Cardiovascular Genetics Laboratory, Hatter Institute for Cardio-
vascular Research in Africa, Department of Medicine, Groote Schuur Hospital and 
University of Cape Town  
Ntobeko B A Ntusi, MB ChB, FCP (SA) 
Gasnat Shaboodien, PhD 
Motasim Badri, PhD (Present address: College of Medicine, King Saud Bin Ab-
delaziz University of Medical Sciences, Riyadh, Kingdom of Saudi Arabia)
Bongani M Mayosi, DPhil, FCP (SA)
Division of Human Genetics, Departments of Clinical Laboratory Sciences and Medi-
cine, University of Cape Town  
Ambroise Wonkam, MD
Frequency and clinical genetics of familial dilated 
cardiomyopathy in Cape Town: Implications for the evaluation 
of patients with unexplained cardiomyopathy
Ntobeko B A Ntusi, Ambroise Wonkam, Gasnat Shaboodien, Motasim Badri, Bongani M Mayosi
Background. Studies from Europe and North America suggest that 
20 - 50% of patients with dilated cardiomyopathy (DCM) may have 
familial disease. There is little information on the frequency and 
clinical genetics of familial DCM in Africa.
Purpose. To determine the frequency and probable mode of 
inheritance of familial DCM in patients referred for investigation 
of the cause of DCM at a tertiary centre in Cape Town.
Methods. We conducted a retrospective analysis of consecutive 
patients diagnosed with DCM between 1 February 1996 and 31 
December 2009 to determine the frequency of familial disease. 
Results. Of 109 unrelated patients with DCM, 29 (26.6%) had 
familial disease. Their mean age of onset of cardiomyopathy (28.01 
(standard deviation (SD) 15.33) years) was significantly younger 
than that for non-familial cases (39.1 (SD 12.6) years) (p=0.001). 
Male predominance (N=21, 72.4%) and racial distribution (15 
(48.3%) coloured patients, 10 (34.5%) black Africans, 4 (13.8%) 
white individuals, and 1 (3.4%) of Indian descent) of familial DCM 
probands were similar to the non-familial cases. Of the 29 patients 
with familial DCM, 2 (7%) had at least one relative diagnosed with 
peripartum cardiomyopathy. Pedigree analysis of the 29 families 
was consistent with autosomal dominant inheritance in 72.4%, 
autosomal recessive inheritance in 17.2% and X-linked recessive 
inheritance in 10.4%. 
Conclusions. Familial DCM affects at least a quarter of African 
patients with DCM, presents at a young age, is associated with 
peripartum cardiomyopathy, and follows an autosomal dominant 
pattern of inheritance in the majority of families. Family screening 
for familial DCM is indicated in all cases of unexplained DCM, 
including patients with peripartum cardiomyopathy.
S Afr Med J 2011;101:394-398.
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50% on echocardiography or cardiac catheterisation. Patients with 
any of the following conditions were excluded:  rheumatic or other 
intrinsic valvular heart disease, coronary artery disease, pericardial 
disease, chronic hypertension, congenital heart disease, and any 
other systemic disease with cardiovascular sequelae such as diabetes, 
drug-induced cardiomyopathy, haemochromatosis, neuromuscular 
disease, infantile endocardial fibro-elastosis, endomyocardial fibrosis, 
amyloidosis, or myocarditis documented on endomyocardial biopsy 
or associated with proven viral infection. Patients who drank alcohol 
were included, since such persons may have a genetic predisposition 
to DCM and their exclusion could spuriously inflate the proportion 
of patients with familial DCM because a diagnosis of alcohol-induced 
cardiomyopathy might be made more readily in the absence of a 
family history of DCM. For similar reasons, patients with peripartum 
cardiomyopathy were included. However, patients with hypertrophic, 
restrictive and tachycardia-related cardiomyopathies were excluded. 
Clinical genetics
A two- to five-generation family pedigree was constructed for 
every patient with DCM. If a subject with DCM had any first-
degree relative who was also affected with DCM, those first-
degree relatives were invited for screening for DCM by history, 
physical examination, electrocardiogram (ECG), echocardiography 
and cardiac catheterisation where indicated. For deceased relatives, 
medical records were reviewed when available. Relatives with other 
cardiac disorders that could account for left ventricular dysfunction 
were excluded. Pedigree analysis was performed for all affected 
families to ascertain the probable pattern of inheritance of familial 
DCM. Pedigrees were constructed using the Cyrillic 2.1 software 
programme (http://www.cyrillicsoftware.com/). 
Statistical analysis
Results of quantitative variables are given as mean (standard 
deviation (SD)). Categorical variables are represented as number and 
percentage. Pearson’s chi-square or Fisher’s exact test was used to 
compare the relative frequency of characteristics between individuals. 
All p-values are two-sided, and p-values <0.05 are considered to 
indicate statistical significance. 
Ethical considerations
The study was approved by the University of Cape Town Faculty of 
Health Sciences Human Research Ethics Committee (REC Ref. No. 
197/96). Participants gave written informed consent. All eligible 
patients were asked for permission to invite their first-degree relatives 
(parents, siblings and children) to participate. 
Results
Frequency of familial DCM
Of 109 unrelated cases with DCM studied, 29 (26.6%) had familial 
DCM. They were derived from all the populations of Cape Town 
and reflected the referral base of GSH, with 15 (48.3%) coloured/
of mixed ancestry, 10 (34.5%) black African, 4 (13.8%) white, and 1 
(3.4%) of Indian descent. A total of 40 individuals with familial DCM 
were finally identified through family screening of the 29 original 
unrelated patients. 
Characteristics of patients with familial DCM
The 29 unrelated cases with familial DCM had a mean age at 
diagnosis of 28.01 (SD 15.3) years, with a preponderance of males 
(N=21, 72.4%); their characteristics were comparable to the total of 
40 individuals with familial DCM from the 29 families studied (i.e. 
72.5% of them were male, with a mean age at the time of diagnosis 
of familial DCM of 25.58 (SD 15.1) years). The age of the individuals 
with familial DCM was significantly lower than that of patients with 
non-familial DCM, who had a mean age of 39.1 (SD 12.6) years at the 
time of diagnosis (p=0.001) (Table I). 
There was no difference in degree of effort intolerance measured 
by New York Heart Association functional class at presentation 
between the index cases with familial and non-familial DCM (Table 
I). The patients with familial and non-familial DCM also had similar 
heart rates and mean systolic blood pressures at presentation (i.e. 95.6 
(SD 23.3) v. 94.9 (SD 19.5) beats/min (p=0.496) and 100.1 (SD 14.9) v. 
101.8 (SD 18.1) mmHg (p=0.397), respectively). While the frequency 
of ECG left bundle-branch block was lower in the familial cases 
(17.2%) compared with the non-familial cases (36.3%), the difference 
was not statistically significant (p=0.123). However, patients with 
familial DCM had significantly less ventricular dilation than the non-
familial cases, the left ventricular end-diastolic dimension (LVEDD) 
being 6.2 (SD 1.1) cm in the familial group versus 6.8 (SD 1.4) cm in 
the non-familial group (p=0.001) (Table I). 
Clinical genetics of familial DCM
Table II summarises the pedigree analysis of the families with DCM 
that were studied. Pedigree analysis of the 29 families was consistent 
with AD inheritance in 21 families (72.4%). An autosomal recessive 
(AR) inheritance pattern was observed in 5 families (17.2%). X-linked 
recessive (X-LR) inheritance was seen in 3 (10.4%) of the familial DCM 
families. The examples of family pedigrees with AD, AR, and X-LR 
inheritance are depicted in Fig. 1, and the full list of pedigrees is available 
online at http://www.medicine.uct.ac.za/Supplementary%20File%20
-%20Figure%202.DOC
The number of affected first-degree relatives per family was 2.16 
(SD 1.14). In these 29 families with DCM, the number of first-degree 
relatives at risk was 3.45 (SD 2.23) per family. One family (3.4%) had 
a clear history of a member with sudden cardiac death before the age 
of 35 years. Of the 29 families included in the analysis, 9 (31.0%) had 
second-degree relatives who were affected.
It is noteworthy that 2 of the 29 unrelated patients (7%) with 
familial DCM had at least one relative diagnosed with peripartum 
cardiomyopathy, confirming that some cases of peripartum 
cardiomyopathy are part of the spectrum of familial DCM.
Discussion
The first familial cases of cardiomyopathy were reported in 1949;14 
subsequently there have been many publications on familial DCM. 
This study extends the observations made in Western populations to 
Africa.15 We show that familial DCM occurs in 26.6% of cases of DCM 
and is a disease of young males with an AD pattern of inheritance in 
the majority of families. We also confirm that some cases of peripartum 
cardiomyopathy, which occurred in the context of familial DCM in 2 
families, are part of the spectrum of familial DCM.16
Our finding of familial disease in a quarter of DCM patients is in 
line with the findings of others, who have found inherited disease to 
constitute 20 - 50% of DCM.5-8,17,18 A prospective echocardiographic 
study that screened first-degree relatives of patients with DCM 
estimated the rate of familial DCM to be 20.3%,6 as 315 relatives 
of 59 index patients with DCM underwent screening with 
echocardiography, including coronary angiography for those older 
than 40 years in order to exclude coronary artery disease. DCM 
was found in 18 relatives (20% of index patients), whereas only 5% 
had been suspected of having familial disease on the basis of family 
history alone. In another prospective study of 56 probands with 
DCM, the definite familial DCM rate was estimated at 25%, where 
the diagnosis of familial disease was based on first-degree relatives 
396
ORIGINAL ARTICLES
June 2011, Vol. 101, No. 6  SAMJ
Table I. Clinical characteristics of patients with familial and non-familial dilated cardiomyopathy
Characteristic Index cases with familial DCM (N=29) Non-familial DCM (N=80) p-value
Age at diagnosis (yrs) (mean (SD)) 28.01 (15.33) 39.10 (12.6) 0.001
Gender (N (%))
   Males 21 (72.4) 48 (60)
   Females 8 (27.6) 32 (40) 0.260
Ethnicity (N (%))
   Black African 10 (34.5) 35 (43.8)
   White 4 (13.8) 13 (16.3)
   Indian ancestry 1 (3.4) 0 (0)
   Coloured/mixed ancestry 14 (48.3) 32 (40) 0.602
Home language (N (%))
   isiXhosa 8 (27.6) 32 (40)
   English 6 (20.7) 11 (13.8)
   Afrikaans 14 (48.3) 35 (43.8)
   Other 1 (3.4) 2 (2.5) 0.417
NYHA FC (N (%))
   Class I and II 8 (27.6) 19 (23.8)
   Class III and IV 21 (72.4) 61 (76.3) 0.110
Heart rate at initial presentation 
(beats/min) (mean (SD)) 96.02 (17.98) 94.89 (19.53) 0.496
Blood pressure, systolic (mmHg) 
(mean (SD)) 102.37 (15.05) 101.78 (18.11) 0.397
LBBB (%) 5 (17.2) 29 (36.3) 0.123
LVEDD (cm) (mean (SD)) 6.28 (1.19) 6.84 (1.37) 0.026
LVEF (%) (mean (SD)) 28.10 (10.98) 24.68 (11.50) 0.048
DCM = dilated cardiomyopathy; NYHA FC = New York Heart Association functional class; LBBB = left bundle-branch block; LVEDD = left ventricular end-diastolic dimension; LVEF = left 
ventricular ejection fraction.
with a diagnosis of DCM on cardiac catheterisation or autopsy, or a 
first-degree relative with both an echocardiographic LVEDD greater 
than two SD above the mean and a left ventricular ejection fraction 
(LVEF) below 50%.19 When left ventricular enlargement was taken as 
a clinical indicator of DCM, two other studies found the frequency of 
familial DCM to range from 35%20 to 48%.21
Over 70% of our patients with familial DCM were male. This 
male preponderance in DCM has been described previously.22,23 In 
hospital-based studies in sub-Saharan Africa, DCM occurs twice 
as commonly in men as in women.24 A study of 637 DCM patients, 
including 130 patients with familial DCM, found that male patients 
constitute approximately 70% of both non-familial and familial DCM 
cohorts studied.25 
The finding of a younger age of onset of familial DCM compared with 
non-familial disease is also consistent with other studies and compatible 
with a genetic cause.25 An earlier systematic study of familial DCM also 
found it to occur at a younger age (mean age of onset 32 years) compared 
with patients with idiopathic DCM.26 Another study comparing familial 
and non-familial DCM found that only a younger age of onset was 
predictive of familial disease; no other clinical or morphological features 
were useful in distinguishing the two entities from each other.27 Likewise, 
Grünig et al. found that 156 of 445 DCM patients confirmed to have 
familial DCM were much younger than those without familial disease.20 
Early-onset cardiovascular disease is likely to be influenced by genetic 
factors more than late-onset disease.28 
We found that at least 70% of familial DCM families demonstrated 
an AD pattern of inheritance, an observation supported by many 
Table II. Clinical genetics of the 29 families with familial 
DCM
Mode of inheritance (N (%))
   Autosomal dominant 21 (72.4)
   Autosomal recessive 5 (17.2)
   X-linked recessive 3 (10.4)
No. of affected 1st-degree relatives per family 
(mean (SD))
2.16 (1.14)
No. of 1st-degree relatives at risk per family 
(mean (SD))
3.45 (2.23)
No. of families with a family history of SCD (N 
(%))
1 (3.4)
No. of families with affected 2nd-degree relatives 
(N (%))
9 (31)
DCM = dilated cardiomyopathy; SCD = sudden cardiac death under the age of 35 years.
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previous publications. Familial 
DCM has been reported most 
commonly with AD inheritance 
in up to 90% of cases.8,27,29 The 
genetic and clinical heterogeneity 
observed is in keeping with 
causation by multiple genes, 
with gene-environment 
interactions altering expression 
of disease.27 To date, over 25 
mutations have been described 
in autosomal genes that cause 
familial DCM.8,29 Some of the 
commonly mutated genes 
causing the AD type of familial 
DCM include lamin A/C, beta-
myosin heavy chain, alpha-
myosin heavy chain, actin, 
alpha-actinin-2, metavinculin, 
desmin, sarcoglycan, troponin 
T, alpha-tropomyosin, titin and 
phospholamban.8 There are also 
genetic polymorphisms that are 
associated with an increased risk 
of developing DCM in some 
populations.30,31
An AR pattern of inheritance 
may account for up to 10% of 
familial DCM, and is commoner 
in certain ethnic groups and in 
cases of infantile DCM.32 Unlike 
many other studies, we found 
a slightly higher rate of AR 
inheritance, 17.2%. A mutation in 
cardiac troponin I has been shown 
to cause AR DCM in one family.33 
X-linked familial DCM has 
been reported in 5 - 10% of 
cases.23 X-linked types of familial 
DCM usually result from 
mutations in the dystrophin gene, 
which are commonly associated 
with skeletal muscle weakness 
and elevated levels of creatinine 
kinase.8,34,35 In some cases, DCM 
has been the only presenting 
feature of patients with Becker 
muscular dystrophy or in female 
carriers.36 Furthermore, Becker 
muscular dystrophy and DCM 
have been seen in the same 
family, suggesting that it may 
be difficult to draw conclusions 
about phenotype from 
genotype.37,38 The determination 
of inheritance patterns by clinical 
genetic analysis of familial DCM 
is not straightforward. Use of 
family history and construction 
of a three- or four-generation 
family pedigree may not be 
sensitive enough when used 
Fig. 1. Pedigrees and mode of inheritance. Pedigree analysis of the 29 families was consistent with autosomal dominant 
inheritance (e.g. panel A) in 72.4% (N=21), autosomal recessive inheritance (e.g. panel B) in 17.2% (N=5) and X-linked 
recessive inheritance (e.g. panel C) in 10.4% (N=3). Filled symbol = phenotypically affected subject; empty symbol = unaf-
fected subject; circle = woman, square = man; diamond = gender unknown; arrow = proband; bar crossing the symbol = 
deceased. All the pedigrees are available as supplementary material online at http://www.medicine.uct.ac.za/
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alone for screening. Often, the phenotypes of affected individuals 
are not sufficiently specific for familial DCM.13 Furthermore, familial 
DCM demonstrates incomplete penetrance, age-dependent disease 
expression and variable expression.39 Among individuals carrying the 
same gene mutation, there may be wide variability in phenotypic effects 
and disease severity both within and between families. Within the 
same family, the phenotype may range from subtle or no symptoms to 
development of arrhythmia, heart failure, sudden cardiac death, stroke 
or need for cardiac transplantation.8
Our study observations have major implications for clinical 
practice. Inherited forms of cardiomyopathy are frequently responsible 
for heart failure that is otherwise unexplained and often labelled as 
idiopathic cardiomyopathy before a complete evaluation is conducted. 
Evaluation of the patient with unexplained cardiomyopathy should 
include a detailed family history, assessment for the presence of 
syndromic features, family screening and clinical genetic analysis of 
first-degree relatives, and consideration of molecular genetic testing. 
The past 10 years have seen remarkable advances in molecular 
genetics.15 Improved technology has lowered costs and clinical use 
of molecular genetic testing is rapidly expanding in South Africa and 
other parts of the world.40 Genetic counselling about the potential 
risks and benefits of genetic testing is essential in the clinical care of 
individuals and families with inherited heart disease. However, the 
likelihood of finding a responsible gene mutation varies among the 
different types of inherited cardiomyopathy. In both hypertrophic and 
right ventricular forms of cardiomyopathy there is a relatively high 
likelihood of finding a responsible gene mutation when molecular 
genetic testing is properly applied.15,40 In contrast, the identification of 
pathogenic mutations in familial DCM is more challenging because 
of extreme genetic heterogeneity. Nevertheless, the clinical screening 
of family members at risk for an inherited form of cardiomyopathy 
leads to earlier identification, earlier treatment, and improved 
outcomes with or without molecular genetic testing.15,25
This study has the limitations of a retrospective design. 
Because it was conducted in a tertiary referral centre for inherited 
cardiomyopathies there may be a referral bias, which may overestimate 
the true frequency of familial DCM. On the other hand, the number 
of familial DCM cases in our cohort may have been underestimated 
for several reasons. First, a varying spectrum of cardiac abnormalities 
may be present in asymptomatic relatives of patients with familial 
DCM. Hence, familial and sporadic types of the disease are not easily 
distinguishable by family history and clinical screening of first-degree 
relatives in the absence of a ‘gold standard’ for diagnosis. Second, our 
diagnosis of familial DCM was based on family history, and screening 
of first-degree relatives of individuals with a positive family history 
to confirm the presence of familial DCM. It is therefore likely that 
we report the minimum frequency of familial DCM, and that the 
screening of the individuals without a family history is likely to yield 
a higher prevalence of familial disease.21 
Conclusion
We have shown that familial DCM is common in African patients 
with unexplained DCM, occurring in a quarter of DCM patients 
studied. We found that familial DCM has a predilection for males 
and an early age of onset, with the mean age at diagnosis being 28 
years. Over 70% of the affected families demonstrated an AD pattern 
of inheritance. These findings have major implications for the clinical 
evaluation of patients with unexplained cardiomyopathy (including 
those with peripartum cardiomyopathy), in whom family screening 
of first-degree relatives for cardiomyopathy is indicated.
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